skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Listed on Nasdaq as AUPH. After market close today,it was halted pending news.Later it announced positive phase 3 trail results showing that its Voclosporin is much better than Standard of Care in Lupus Nephritis.It plans to file NDA submission to FDA in 1st half of 2020,There will be a conference call @ 8.30am ET on Dec 5 .AUPH closed @ US$8.39 up 0.41 on 4.9m shares.However in After Hours trading it was @ US $18.39 to US$19.00 on total 10.6m shares.Thinking of selling my 1.5% position,p/p Can$8.33 especially if the Price is around US$18.39 to 19.00.Should I sell all or partial.Please provide your usual great advices & services.Thanks
Read Answer Asked by Peter on December 05, 2019
Q: I have been very fortunate to have my second 10-bagger with ARWR bought at $4 in 2017 (after some earlier losses). It has been running very well recently but is down to-day on the news that they are issuing 4m shares at $58, well below yesterdays close of $68.66. Why would they issue new shares so far below the recent market? Is there something here to worry about?
Thanks for your great service, Bob.
Read Answer Asked by Lynn on December 04, 2019
Q: Gud has now 51% and yet BIO trades at $10.15 BRL, about 16% below the offer price.
What do you read into this. Is there an opportunity here ? Can I buy BIO, should I ?
Will GUD offer less than they offered the private previous owners ? When will GUD start reporting earnings from this acquisition ? Do they need all the shares to do so ?
Finally do you see more analysts stepping in now with this new acquisition, maybe one or two will make it their top pick in 2020 ? Thoughts?Thanks
Read Answer Asked by Luc on December 03, 2019
Q: Hi there,

This is a cancer biotech focused on melanoma and cervical cancer. It sounds like several promising trials are underway. I just read about it on Seeking Alpha and CNBC shows 8 analysts covering with 5 strong buy and 3 buy recommendations with a consensus target of $35 vs a current price of $22.83. What are your thoughts regarding a position within a TFSA?

ThanksQ
Read Answer Asked by Tim on December 03, 2019
Q: Hi Peter and Ryan,

I noticed CLVS had a good run lately. I am wondering whether the fundamental has been changed. Is it a good buy now?
Please also provide a few (CAD and US) names that are stable for long investment in the next few months, particularly with good valuation. It is almost RRSP season.
Thanks,
Yiwen
Read Answer Asked by Yiwen on November 29, 2019
Q: Hi folks
I sold SIS at a loss in my non registered account. However I also own it in my TFSA and my RRIF at a gain. Does this make my loss null and void? I may buy it back in my non registered in 30 days. Also you had mentioned that you would like to see SIS break at $14.15... But is it good to buy now (if I decide to add to my TFSA holding).? Or would that also break the 30 day rule?
Thank you again for a good year.
Read Answer Asked by El-ann on November 27, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!